Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, variants, or PubMed publications.

Have questions, comments or suggestions? - Let us know!

Email us at : ckbsupport@jax.org

NCT ID NCT02970318
Title A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLL
Recruitment Active, not recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Acerta Pharma BV
Indications

chronic lymphocytic leukemia

Therapies

Bendamustine + Idelalisib + Rituximab

Acalabrutinib

Age Groups: adult | senior
Covered Countries USA | CAN


No variant requirements are available.